Table 2.
Clinical information of patients presenting MRONJ.
| Data collected from MRONJ manifestations | |||||
|---|---|---|---|---|---|
| Patients | #1 | #2 | #3 | #4 | #5 |
| Age (years) | 66 | 75 | 68 | 55 | 81 |
| Gender | F | F | F | F | F |
| Risk factors | Smoking habits | x | Diabetes | x | x |
| Type of systemic disease | Osteoporosis | Oncological disease | Oncological disease | Oncological disease | Osteoporosis |
| Medication | Alendronate | Ibandronate | Alendronate + 5 − fluorouracil | Ibandronate | Alendronate |
| Route of drug therapy | Oral | Intravenous | Oral | Intravenous | Oral |
| Duration of drug therapy (months) | 88 | 43 | 62 | 69 | 55 |
| Risk associated to CTX | High | High | High | High | High |
| MRONJ stage | 2 | 2 | 2 | 2 | 2 |
| MRONJ site | Anterior mandible | Anterior mandible | Posterior mandible | Posterior mandible | Anterior mandible |
| Number of tooth extracted | 3 | 1 | 2 | 1 | 2 |
| Manifestation of MRONJ after extraction (months) | 2 | 4 | 3 | 4 | 5 |